Biomarker Identified for Novel Asthma Treatment
|
By LabMedica International staff writers Posted on 17 Sep 2018 |

Image: The LSM 780 inverted laser scanning confocal microscope (Photo courtesy of Zeiss).
Asthma is a widespread chronic airway disease characterized by airway obstruction, inflammation, and hyperresponsiveness. Symptoms such as bronchoconstriction and cough range from mild intermittent to severe persistent.
In eosinophilic asthma, the most common form of asthma, eosinophils in the airway alter nerve function and exacerbate the disease. However, whether eosinophils also affect airway nerve structure is unclear. In type 2-high asthma, interleukin-5 (IL-5) promotes eosinophil maturation, recruitment, and survival.
An international team of scientists working with the Oregon Health and Science University (Portland, OR, USA) evaluated airway sensory innervation and eosinophilia in humans with and without asthma and to characterize the physiologic consequences of eosinophil and airway nerve interactions using transgenic mice. Patients over the age of 17 were recruited and medication use, pulmonary function testing, blood eosinophil counts, serum immunoglobulin E (IgE) levels, and smoking history were obtained.
Human bronchial biopsies (three to five per subject) were taken from the bifurcation of the right middle lobe and immediately fixed in formalin overnight. Tissues were immunostained at 4 °C on a shaker. Airway nerves were labeled with rabbit polyclonal antibody against pan-neuronal marker PGP9.5 (protein gene product 9.5), and other immunostaining was performed and images were acquired using a Zeiss LSM 780 confocal microscope.
The scientists reported that subjects with a type 2-high asthma phenotype, defined as blood eosinophils greater than 300 cells/μL, had longer airway nerves and increased nerve branch points compared to control airways. In contrast, nerves in type 2-low asthmatics with blood eosinophils less than 300 cells/μL were not significantly different from healthy subjects. The mean blood eosinophils counts were 182 ± 93 μL in the 19 controls; 277 ± 289/μL in the 13 intermittent asthma patients; and 301 ± 225/μL in the persistent asthma sufferers. Moderate persistent asthmatics had increased eosinophil peroxidase both above and below the epithelial basement membrane compared to mild intermittent asthmatics and control subjects.
The authors concluded that their data indicated that airway nerves contribute to asthma pathology. They have shown that moderate persistent asthmatics have increased airway sensory innervation that is especially marked in asthmatics with accompanying eosinophilia. Richard W. Costello, MB, MD, FRCPI, a professor and a senior author of the study, said, “We identified that inflammatory cells, in particular, eosinophils, promote airway nerve growth in patients with asthma. These observations provide a unique insight into a fundamental mechanism of how the inflammation caused by asthma causes people to experience the symptoms of asthma such as coughing and breathlessness. This means that we now know which markers to look for in a patient with severe asthma. A patient with markers which show they have this particular form of asthma is likely to respond well to these new treatments.” The study was published on September 5, 2018, in the journal Science Translational Medicine.
Related Links:
Oregon Health and Science University
In eosinophilic asthma, the most common form of asthma, eosinophils in the airway alter nerve function and exacerbate the disease. However, whether eosinophils also affect airway nerve structure is unclear. In type 2-high asthma, interleukin-5 (IL-5) promotes eosinophil maturation, recruitment, and survival.
An international team of scientists working with the Oregon Health and Science University (Portland, OR, USA) evaluated airway sensory innervation and eosinophilia in humans with and without asthma and to characterize the physiologic consequences of eosinophil and airway nerve interactions using transgenic mice. Patients over the age of 17 were recruited and medication use, pulmonary function testing, blood eosinophil counts, serum immunoglobulin E (IgE) levels, and smoking history were obtained.
Human bronchial biopsies (three to five per subject) were taken from the bifurcation of the right middle lobe and immediately fixed in formalin overnight. Tissues were immunostained at 4 °C on a shaker. Airway nerves were labeled with rabbit polyclonal antibody against pan-neuronal marker PGP9.5 (protein gene product 9.5), and other immunostaining was performed and images were acquired using a Zeiss LSM 780 confocal microscope.
The scientists reported that subjects with a type 2-high asthma phenotype, defined as blood eosinophils greater than 300 cells/μL, had longer airway nerves and increased nerve branch points compared to control airways. In contrast, nerves in type 2-low asthmatics with blood eosinophils less than 300 cells/μL were not significantly different from healthy subjects. The mean blood eosinophils counts were 182 ± 93 μL in the 19 controls; 277 ± 289/μL in the 13 intermittent asthma patients; and 301 ± 225/μL in the persistent asthma sufferers. Moderate persistent asthmatics had increased eosinophil peroxidase both above and below the epithelial basement membrane compared to mild intermittent asthmatics and control subjects.
The authors concluded that their data indicated that airway nerves contribute to asthma pathology. They have shown that moderate persistent asthmatics have increased airway sensory innervation that is especially marked in asthmatics with accompanying eosinophilia. Richard W. Costello, MB, MD, FRCPI, a professor and a senior author of the study, said, “We identified that inflammatory cells, in particular, eosinophils, promote airway nerve growth in patients with asthma. These observations provide a unique insight into a fundamental mechanism of how the inflammation caused by asthma causes people to experience the symptoms of asthma such as coughing and breathlessness. This means that we now know which markers to look for in a patient with severe asthma. A patient with markers which show they have this particular form of asthma is likely to respond well to these new treatments.” The study was published on September 5, 2018, in the journal Science Translational Medicine.
Related Links:
Oregon Health and Science University
Latest Immunology News
- Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
- Compact Immunoanalyzer Gains CE Mark for Testing Across Local Care Settings
- COVID-19 and Flu Combo Test Launches With FDA Clearance
- Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
- Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
- Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
- Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
- Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
- FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
- Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
- Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
- Prototype Point-of-Care Test Aims to Improve Neonatal Sepsis Diagnosis
- Single-Tier Lyme Disease Test Shows High Sensitivity in Early Infection
- New Web-Based Platform Helps Autoimmune Laboratories Manage Testing Complexity
- Routine Newborn Blood Spots Can Measure GBS Antibody Levels
- New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreMolecular Diagnostics
view channel
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
Natera (Austin, TX, USA) presented findings from 25 abstracts, including nine oral presentations, at the ESMO Congress 2026 in Madrid. The research examined circulating tumor DNA (ctDNA) testing for molecular... Read moreImmunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read moreMicrobiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read moreIndustry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more







